A Paradigm Shift in First-Line Treatment Can Have Many Implications For Second-Line Treatment

Affiliations

¹ Department of Pulmonary Medicine, Mie Chuo Medical Center Mie, Japan; Department of Pulmonary and Critical Care Medicine, Mie University Graduate School of Medicine, Mie, Japan. Electronic address: shidatafireflash@gmail.com.

Free article

Comment

Tadashi Nishimura. J Thorac Oncol. 2024 Feb.

Free article

. 2024 Feb;19(2):350.

doi: 10.1016/j.jtho.2023.11.006.

¹ Department of Pulmonary Medicine, Mie Chuo Medical Center Mie, Japan; Department of Pulmonary and Critical Care Medicine, Mie University Graduate School of Medicine, Mie, Japan. Electronic address: shidatafireflash@gmail.com.

No abstract available

Comment in

A Response to the Letter to the Editor: "A Paradigm Shift in First-Line Treatment Can Have Many Implications for Second-Line Treatment".
Torasawa M, Horinouchi H. Torasawa M, et al. J Thorac Oncol. 2024 Feb;19(2):351-352. doi: 10.1016/j.jtho.2023.12.004. J Thorac Oncol. 2024. PMID: 38325987 No abstract available.

Reconsidering the Cutoff Value for Sensitive and Refractory Relapses in Extensive-Stage SCLC in the Era of Immunotherapy.
Torasawa M, Horinouchi H, Nomura S, Igawa S, Asai M, Ishii H, Wakui H, Ushio R, Asao T, Namba Y, Koyama R, Hayakawa D, Katayama I, Matsuda H, Sasaki S, Takahashi K, Hosomi Y, Naoki K, Ohe Y. Torasawa M, et al. J Thorac Oncol. 2024 Feb;19(2):325-336. doi: 10.1016/j.jtho.2023.09.1446. Epub 2023 Sep 23. J Thorac Oncol. 2024. PMID: 37748690